Use of linezolid for gram-positive infections

Infections in Medicine

Volumn 19, Issue 1, 2002, Pages 25-32

  Linden, Peter ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bacteria, gram positive; Enterococci; Oxazolidinones; Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BACTOCILL; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; CLINDETS; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DECONGESTIVE AGENT; DICLOXACILLIN; ERY TAB; ERYTHROMYCIN; LINEZOLID; METICILLIN; MONOAMINE OXIDASE INHIBITOR; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINUPRISTIN; SEROTONIN UPTAKE INHIBITOR; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYCOSIS; NAUSEA; SKIN INFECTION; TASTE DISORDER; VOMITING;

EID: 0036155293     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
2. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Therapeutic realities and possibilities
3. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
4. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance
5. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
6. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E faecium
7. Emergence of vancomycin resistance in Staphylococcus aureus Glycocpeptide-Intermediate Staphylococcus aureus Working Group
8. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
9. The economic impact of bacteremia due to vancomycin-resistant Enterococcus faecium: A case-control study
10. FDA approves Zyvox, the first antimicrobial drug in a new class
11. Oxazolidinone antibacterial agents
12. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
13. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents
14. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
15. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
16. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) verus vancomycin against Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium
17. Linezolid safety, tolerance and pharmacokinetics after intravenous dosing twice daily for 7.5 days
18. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailibility of linezolid
19. In vitro metabolism of linezolid (PNU-100766); lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586
20. Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) following oral administration of {14C} PNU-100766 to healthy volunteers
21. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
22. Although a novel microtiter-plate assay demonstrates that linezolid is a weak, competitive (reversible) inhibitor of human monoamine oxidase A (MAO A) no clinical evidence of MAO A inhibition in phase II or III been observed
23. Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial
24. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
25. Efficacy of linezolid in community-acquired Spneumoniae pneumonia
26. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia
27. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of therapy with Synercid (quinupristin/dalfopristin)
28. Comparison of hospital length of stay for patients with known or suspected methicillin-resistant Staphylococcus species infection treated with linezolid or vancomycin: A randomized multicenter trial
29. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram-positive infections
30. Linezolid and reversible myelosuppression
31. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid
32. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
33. Linezolid resistance in a clinical isolate of Staphylococcus aureus
34. Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci
35. Cost considerations in the evaluation of new therapies for gram-positive bacteria